Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pacritinib - CTI BioPharma

Drug Profile

Pacritinib - CTI BioPharma

Alternative Names: ENPAXIQ; Epjevy; ONX-0803; Pacritinib; Pacritinib citrate; Pacritinibum; SB-1518

Latest Information Update: 16 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; Ohio State University Comprehensive Cancer Center; S*BIO; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Phase I/II Graft-versus-host disease
  • Phase I Haematological disorders
  • Preclinical Chronic myeloid leukaemia
  • Suspended Colorectal cancer
  • Discontinued Lymphoma

Most Recent Events

  • 03 Feb 2020 CTI BioPharma announces intention to submit NDA to US FDA for Myelofibrosis in early 2022
  • 07 Dec 2019 Safety and efficacy data from the phase II PACIFICA trial in Myelofibrosis presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top